Efficacy of tigilanol tiglate in dogs with mast cell tumors

Mast cell tumor (MCT) is the most common skin tumor in dogs; information regarding response rate to tigilanol tiglate for MCT in dogs is limited. The objective of this multicenter, retrospective study was to report the response rate and durability of tigilanol tiglate intratumoral treatment in dogs with mast cell tumors presented to veterinary oncologists. Veterinary oncologists subscribed to the American College of Veterinary Internal Medicine (ACVIM) oncology listserv were solicited for information from dogs treated with tigilanol tiglate. An electronic survey was used to collect information at initial treatment, 1 month and 1 year after treatment. One hundred forty-nine dogs, with ...

To read the full article you must log in with your EGO codes.

Use your EGO login data to access Vet.Journal

Username

Password Show Password

Remember Me

Sign in with a passkey

Log in

• Forgot your password?
• Forgot your username?

Check who can access Vet.Journal